Key result
GNAQ TT/TT genotype linked to ~93% higher cardiovascular event risk in dialysis patients.
Why the study?
Single-nucleotide polymorphisms in G protein subunits are linked to increased cardiovascular risk in the general population, but their effects in patients undergoing renal replacement therapy were evaluated.
Do GNB3, GNAQ, and GNAS polymorphisms increase the risk of cardiovascular events in patients undergoing renal replacement therapy?
Cohort (n=454)
Do GNB3, GNAQ, and GNAS polymorphisms increase the risk of cardiovascular events in patients undergoing renal replacement therapy?
Effect estimate: HR 1.93
p-value: p=0.04
GNAQ and GNB3 polymorphisms are associated with an increased risk of coronary artery stenosis, severe cardiovascular events, and left ventricular dilatation in patients on dialysis.
Single-nucleotide polymorphisms in G protein subunits are linked to an increased risk of cardiovascular events among the general population. We assessed the effects of GNB3 c.825C > T, GNAQ −695/−694GC > TT, and GNAS c.393C > T polymorphisms on the risk of cardiovascular events among 454 patients undergoing renal replacement therapy. The patients were followed up for a median of 4.5 years after the initiation of dialysis. Carriers of the TT/TT genotype of GNAQ required stenting because of coronary artery stenosis (p = 0.0009) and developed cardiovascular events involving more than one organ system (p = 0.03) significantly earlier and more frequently than did the GC/TT or GC/GC genotypes. Multivariate analysis found that the TT/TT genotype of GNAQ was an independent risk factor for coronary artery stenosis requiring stent (hazard ratio, 4.5; p = 0.001), cardiovascular events (hazard ratio, 1.93; p = 0.04) and cardiovascular events affecting multiple organs (hazard ratio, 4.9; p = 0.03). In the subgroup of male patients left ventricular dilatation with abnormally increased LVEDD values occurred significantly more frequently in TT genotypes of GNB3 than in CT/CC genotypes (p = 0.007). Our findings suggest that male dialysis patients carrying the TT genotype of GNB3 are at higher risk of left ventricular dilatation and that dialysis patients carrying the TT/TT genotype of GNAQ are prone to coronary artery stenosis and severe cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Birkner et al. (2023) conducted a cohort in Renal replacement therapy (n=454). GNAQ and GNB3 polymorphisms vs. Non-carriers (e.g., GC/TT or GC/GC genotypes) was evaluated on Cardiovascular events (HR 1.93, p=0.04). The TT/TT genotype of GNAQ was an independent risk factor for cardiovascular events (HR 1.93; p=0.04) and coronary artery stenosis requiring stenting (HR 4.5; p=0.001) in dialysis patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: